BRAF and melanoma: A peculiar role of NONO has been described in nearly half of melanoma patients carrying the mutation V600E in the BRAF kinase; for this subset of patients, BRAF inhibitors show a significant antitumor response, but the common emergence of acquired resistance remains a challenge.